Health Affairs, 24, no. 3 (2005): 718-728 doi: 10.1377/hlthaff.24.3.718 © 2005 by Project HOPE	New Online   McAllen, TX & Beyond: An Expert Roundtable   Geography & Reform   Medicaid or Insurance Exchange?   Siren Song of New GME   Public Plan Option: Pro & Con

This Article Full Text (HTML) Reprint (PDF) Submit a response to this article Alert me when this article is cited Alert me when Comments are posted Alert me if a correction is posted Services E-mail this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Archive Download to Citation Manager Reprints & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Milstien, J. Articles by Wikler, D. Search for Related Content PubMed PubMed Citation Articles by Milstien, J. Articles by Wikler, D. Related Collections Health Promotion/Disease Prevention International Issues Public Health Research And Technology Consumer Issues Vaccines

Implementation

Development Of Priority Vaccines For Disease-Endemic Countries: Risk And Benefit

Decisions regarding vaccine regulation and use made by institutions in industrialized countries can have an unintended impact on vaccines’ availability in disease-endemic countries. However, regulatory and programmatic decision making by such countries, taking into consideration local risks and benefits, requires adequate resources, both human and financial. Such differing risk-benefit determinations between industrialized and disease-endemic countries will increase product divergence. We propose a single universal standard for risk assessment, based on maximizing net benefit, and an action plan to improve access to priority vaccines through a more robust determination of risk and benefit.

                      What's this?